Effectiveness of repeated treatment with botulinum toxin type A across different conditions

Southern Medical Journal

Volumn 99, Issue 8, 2006, Pages 853-861

  Gordon, Mark Forrest ^b   Barron, Rich ^a  

^a ALLERGAN INC   (United States)

^b NONE

Author keywords

Cerebral palsy; Dystonia; Muscle tone; Spasticity

Indexed keywords

BOTULINUM TOXIN A;

ANTIBODY PRODUCTION; CEREBRAL PALSY; CLINICAL TRIAL; DIZZINESS; DRUG EFFICACY; DYSTONIA; HEMIFACIAL SPASM; HUMAN; MUSCLE TONE; REVIEW; SOMNOLENCE; SPASTICITY;

BOTULINUM TOXIN TYPE A; CEREBRAL PALSY; DYSKINESIAS; HUMANS; MUSCLE SPASTICITY; NEUROMUSCULAR AGENTS; RETREATMENT; TREATMENT OUTCOME;

EID: 33747183995     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.smj.0000220888.88722.ab     Document Type: Review

References (93)

1. Verheyden J, Blitzer A, Brin MF. Other noncosmetic uses of BOTOX. Semin Cutan Med Surg 2001;20:121-126.
2. Carruthers A, Carruthers J, Lowe NJ, et al. One-year, randomised, multicenter, two-period study of the safety and efficacy of repeated treatments with botulinum toxin type A in patients with glabellar lines. J Clin Res 2004;7:1-20.
3. Relja M, Telarovic S. Botulinum toxin in tension-type headache. J Neurol 2004;251 (Suppl I):I12-I14.
4. Childers MK, Wilson DJ, Gnatz SM, et al. Botulinum toxin type A use in piriformis muscle syndrome: a pilot study. Am J Phys Med Rehabil 2002;81:751-759.
5. Naumann M, Lowe NJ, Kumar CR, et al. Botulinum toxin type A is a safe and effective treatment for axillary hyperhidrosis over 16 months: a prospective study. Arch Dermatol 2003;139:731-736.
6. Simpson LL. The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol Rev 1981;33:155-188.
7. MacKenzie I, Burnstock G, Dolly JO. The effects of purified botulinum neurotoxin type A on cholinergic, adrenergic and non-adrenergic, atropine-resistant autonomic neuromuscular transmission. Neuroscience 1982;7:997-1006.
8. Ambache N. A further survey of the action of Clostridium botulinum toxin upon different types of autonomic nerve fibre. J Physiol 1951;113:1-17.
9. Welch MJ, Purkiss JR, Foster KA. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 2000;38:245-258.
10. Durham PL, Cady R, Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 2004;44:35-42.
11. Aoki KR. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 2003;43(Suppl 1):S9-S15.
12. Dutton JJ, Buckley EG. Long-term results and complications of botulinum A toxin in the treatment of blepharospasm. Ophthalmology 1988;95:1529-1534.
13. Elston JS. The management of blepharospasm and hemifacial spasm. J Neurol 1992;239:5-8.
14. Jankovic J, Schwartz KS. Longitudinal experience with botulinum toxin injections for treatment of blepharospasm and cervical dystonia. Neurology 1993;43:834-836.
15. Lagalla G, Danni M, Reiter F, et al. Post-stroke spasticity management with repeated botulinum toxin injections in the upper limb. Am J Phys Med Rehabil 2000;79:377-384.
16. Garcia Ruiz PJ, Pascual Pascual I, Sanchez Bernardos V. Progressive response to botulinum A toxin in cerebral palsy. Eur J Neurol 2000;7:191-193.
17. Blumenfeld A. Botulinum toxin type A as an effective prophylactic treatment in primary headache disorders. Headache 2003;43:853-860.
18. Jankovic J. Blepharospasm and oromandibular-laryngeal-cervical dystonia: a controlled trial of botulinum A toxin therapy. Adv Neurol 1988;50:583-591.
19. Jankovic J, Schwartz K, Donovan DT. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry 1990;53:633-639.
20. Blitzer A, Brin MF, Stewart CF. Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients. Laryngoscope 1998;108:1435-1441.
21. Arad-Cohen A, Blitzer A. Botulinum toxin treatment for symptomatic Frey's syndrome. Otolaryngol Head Neck Surg 2000;122:237-240.
22. Tsoy EA, Buckley EG, Dutton JJ. Treatment of blepharospasm with botulinum toxin. Am J Ophthalmol 1985;99:176-179.
23. Maurri S, Brogelli S, Alfieri G, et al. Beneficial effect of botulinum A toxin in blepharospasm: 16 months' experience with 16 cases. Ital J Neurol Sci 1988;9:337-344.
24. Matarasso SL, Matarasso A. Treatment guidelines for botulinum toxin type A for the periocular region and a report on partial upper lip ptosis following injections to the lateral canthal rhytids. Plast Reconstr Surg 2001;108:208-214.
25. Boyd RN, Graham JEA, Nattrass GR, et al. Medium-term response characterization and risk factor analysis of botulinum toxin type A in the management of spasticity in children with cerebral palsy. Eur J Neurol 1999;6(Suppl 4):S37-S45.
26. Brin MF, Fahn S, Moskowitz C, et al. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord 1987;2:237-254.
27. Bulstrode NW, Grobbelaar AO. Long-term prospective follow-up of botulinum toxin treatment for facial rhytides. Aesthetic Plast Surg 2002;26:356-359.
28. Vela MF, Richter JE, Wachsberger D, et al. Complexities of managing achalasia at a tertiary referral center: use of pneumatic dilatation, Heller myotomy, and botulinum toxin injection. Am J Gastroenterol 2004;99:1029-1036.
29. Neubrand M, Scheurlen C, Schepke M, et al. Long-term results and prognostic factors in the treatment of achalasia with botulinum toxin. Endoscopy 2002;34:519-523.
30. Niamtu J III. Botulinum toxin A: a review of 1,085 oral and maxillofacial patient treatments. J Oral Maxillofac Surg 2003;61:317-324.
31. Tsui JK, Fross RD, Calne S, et al. Local treatment of spasmodic torticollis with botulinum toxin. Can J Neurol Sci 1987;14(3 Suppl):533-535.
32. Pullman SL, Greene P, Fahn S, et al. Approach to the treatment of limb disorders with botulinum toxin A: experience with 187 patients. Arch Neurol 1996;53:617-624.
33. Tan EK, Jankovic J. Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up. Neurology 1999;53:2102-2107.
34. Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 1994;9:213-217.
35. Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology 1995;45:1743-1746.
36. Erdal J, Ostergaard L, Fuglsang-Frederiksen A, et al. Long-term botulinum toxin treatment of cervical dystonia: EMG changes in injected and noninjected muscles. Clin Neurophysiol 1999;110:1650-1654.
37. Borodic GE, Ferrante R. Effects of repeated botulinum toxin injections on orbicularis oculi muscle. J Clin Neuroophthalmol 1992;12:121-127.
38. Physician's Desk Reference. BOTOX® (Botulinum Toxin Type A). Montvale, NJ, Thomson PDR, 2003, pp 552-554.
39. Calace P, Cortese G, Piscopo R, et al. Treatment of blepharospasm with botulinum neurotoxin type A: long-term results. Eur J Ophthalmol 2003;13:331-336.
40. Shorr N, Seiff SR, Kopelman J. The use of botulinum toxin in blepharospasm. Am J Ophthalmol 1985;99:542-546.
41. Dutton JJ, Buckley EG. Botulinum toxin in the management of blepharospasm. Arch Neurol 1986;43:380-382.
42. Elston JS. Long-term results of treatment of idiopathic blepharospasm with botulinum toxin injections. Br J Ophthalmol 1987;71:664-668.
43. Ainsworth JR, Kraft SP. Long-term changes in duration of relief with botulinum toxin treatment of essential blepharospasm and hemifacial spasm. Ophthalmology 1995;102:2036-2040.
44. Snir M, Weinberger D, Bourla D, et al. Quantitative changes in botulinum toxin a treatment over time in patients with essential blepharospasm and idiopathic hemifacial spasm. Am J Ophthalmol 2003;136:99-105.
45. Nussgens Z, Roggenkamper P. Long-term treatment of blepharospasm with botulinum toxin type A. Ger J Ophthalmol 1995;4:363-367.
46. Engstrom PF, Arnoult JB, Mazow ML, et al. Effectiveness of botulinum toxin therapy for essential blepharospasm. Ophthalmology 1987;94:971-975.
47. Drummond GT, Hinz BJ. Botulinum toxin for blepharospasm and hemifacial spasm: stability of duration of effect and dosage over time. Can J Ophthalmol 2001;36:398-403.
48. Ruusuvaara P, Setala K. Long-term treatment of involuntary facial spasms using botulinum toxin. Acta Ophthalmol (Copenh) 1990;68:331-338.
49. Defazio G, Abbruzzese G, Girlanda P, et al. Botulinum toxin A treatment for primary hemifacial spasm: a 10-year multicenter study. Arch Neurol 2002;59:418-420.
50. Gonnering RS. Treatment of hemifacial spasm with botulinum A toxin: results and rationale. Ophthal Plast Reconstr Surg 1986;2:143-146.
51. Flanders M, Chin D, Boghen D. Botulinum toxin: preferred treatment for hemifacial spasm. Eur Neurol 1993;33:316-319.
52. Chen RS, Lu CS, Tsai CH. Botulinum toxin A injection in the treatment of hemifacial spasm. Acta Neurol Scand 1996;94:207-211.
53. Jankovic J, Schwartz K. Botulinum toxin injections for cervical dystonia. Neurology 1990;40:277-280.
54. Dubinsky RM, Gray CS, Vetere-Overfield B, et al. Electromyographic guidance of botulinum toxin treatment in cervical dystonia. Clin Neuropharmacol 1991;14:262-267.
55. Brashear A, Watts MW, Marchetti A, et al. Duration of effect of botulinum toxin type A in adult patients with cervical dystonia: a retrospective chart review. Clin Ther 2000;22:1516-1524.
56. Hsiung GY, Das SK, Ranawaya R, et al. Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period. Mov Disord 2002;17:1288-1293.
57. Damrose JF, Goldman SN, Groessl EJ, et al. The impact of long-term botulinum toxin injections on symptom severity in patients with spasmodic dysphonia. J Voice 2004;18:415-422.
58. Ludlow CL, Bagley J, Yin SG, et al. A comparison of injection techniques using botulinum toxin injection for treatment of the spasmodic dysphonias. J Voice 1992;6:380-386.
59. Rubin AD, Wodchis WP, Spak C, et al. Longitudinal effects of Botox injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia: part II. Arch Otolaryngol Head Neck Surg 2004;130:415-420.
60. Hogikyan ND, Wodchis WP, Spak C, et al. Longitudinal effects of botulinum toxin injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia. J Voice 2001;15:576-586.
61. Aronson AE, McCaffrey TV, Litchy WJ, et al. Botulinum toxin injection for adductor spastic dysphonia: patient self-ratings of voice and phonatory effort after three successive injections. Laryngoscope 1993;103:683-692.
62. Mehta RP, Goldman SN, Orloff LA. Long-term therapy for spasmodic dysphonia: acoustic and aerodynamic outcomes. Arch Otolaryngol Head Neck Surg 2001;127:393-399.
63. Balkrishnan R, Manuel JC, Smith BP, et al. Longitudinal examination of health outcomes associated with botulinum toxin use in children with cerebral palsy. J Surg Orthop Adv 2004;13:76-80.
64. Koman LA, Brashear A, Rosenfeld S, et al. Botulinum toxin type a neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: a multicenter, open-label clinical trial. Pediatrics 2001;108:1062-1071.
65. Rodriguez AA, McGinn M, Chappell R. Botulinum toxin injection of spastic finger flexors in hemiplegic patients. Am J Phys Med Rehabil 2000;79:44-47.
66. Gordon MF, Brashear A, Elovic E, et al. Repeated dosing of botulinum toxin type A for upper limb spasticity following stroke. Neurology 2004;63:1971-1973.
67. Acquadro MA, Borodic GE. Treatment of myofascial pain with botulinum A toxin. Anesthesiology 1994;80:705-706.
68. Wehrmann T, Kokabpick H, Jacobi V, et al. Long-term results of endoscopic injection of botulinum toxin in elderly achalasic patients with tortuous megaesophagus or epiphrenic diverticulum. Endoscopy 1999;31:352-358.
69. D'Onofrio V, Annese V, Miletto P, et al. Long-term follow-up of achalasic patients treated with botulinum toxin. Dis Esophagus 2000;13:96-101.
70. Annese V, Basciani M, Borrelli O, et al. Intrasphincteric injection of botulinum toxin is effective in long-term treatment of esophageal achalasia. Muscle Nerve 1998;21:1540-1542.
71. Allescher HD, Storr M, Seige M, et al. Treatment of achalasia: botulinum toxin injection vs pneumatic balloon dilation: a prospective study with long-term follow-up. Endoscopy 2001;33:1007-1017.
72. Kolbasnik J, Waterfall WE, Fachnie B, et al. Long-term efficacy of Botulinum toxin in classical achalasia: a prospective study. Am J Gastroenterol 1999;94:3434-3439.
73. Storr M, Allescher HD, Rosch T, et al. Treatment of symptomatic diffuse esophageal spasm by endoscopic injections of botulinum toxin: a prospective study with long-term follow-up. Gastrointest Endosc 2001;54:754-759.
74. Lewin JS, Bishop-Leone JK, Forman AD, et al. Further experience with Botox injection for tracheoesophageal speech failure. Head Neck 2001;23:456-460.
75. Lowe PL, Cerdan-Sanz S, Lowe NJ. Botulinum toxin type A in the treatment of bilateral primary axillary hyperhidrosis: efficacy and duration with repeated treatments. Dermatol Surg 2003;29:545-548.
76. Giannantoni A, Mearini E, Di Stasi SM, et al. New therapeutic options for refractory neurogenic detrusor overactivity. Minerva Urol Nefrol 2004;56:79-87.
77. Mauriello Jr, JA Dhillon S, Leone T, et al. Treatment selections of 239 patients with blepharospasm and Meige syndrome over 11 years. Br J Ophthalmol 1996;80:1073-1076.
78. Mauriello JA Jr., Leone T, Dhillon S, et al. Treatment choices of 119 patients with hemifacial spasm over 11 years. Clin Neurol Neurosurg 1996;98:213-216.
79. Mauriello JA, Aljian J. Natural history of treatment of facial dyskinesias with botulinum toxin: a study of 50 consecutive patients over seven years. Br J Ophthalmol 1991;75:737-739.
80. Brashear A, Bergan K, Wojcieszek J, et al. Patients' perception of stopping or continuing treatment of cervical dystonia with botulinum toxin type A. Mov Disord 2000;15:150-153.
81. Karp BI, Cole RA, Cohen LG, et al. Long-term botulinum toxin treatment of focal hand dystonia. Neurology 1994;44:70-76.
82. Damron TA, Greenwald TA, Breed AL. Chronologic outcome of surgical tendoachilles lengthening and natural history of gastroc-soleus contracture in cerebral palsy: a two-part study. Clin Orthop Relat Res 1994;301:249-255.
83. Ludlow CL, Hallett M, Sedory SE, et al. The pathophysiology of spasmodic dysphonia and its modification by botulinum toxin. In: Berardelli A, Benecke R, Manfredi M, Marsden CM (eds).Motor Disturbances II. New York, Academic Press, 1990, pp 273-288.
84. Brin MF, Blitzer A, Stewart C, et al. Treatment of spasmodic dysphonia (laryngeal dystonia) with local injections of botulinum toxin: review and technical aspects. In: Blitzer A, Brin MF, Sasaki CT, Fahn S, Harris KS (eds). Neurological Disorders of the Larynx. New York, Thieme, 1992, pp 214-228.
85. Zwirner P, Murry T, Swenson M, et al. Effects of botulinum toxin therapy in patients with adductor spasmodic dysphonia: acoustic, aerodynamic, and videoendoscopic findings. Laryngoscope 1992;102:400-406.
86. Giladi N, Meer J, Kidan H, et al. Long-term remission of idiopathic cervical dystonia after treatment with botulinum toxin. Eur Neurol 2000;44:144-146.
87. Filippi GM, Errico P, Santarelli R, et al. Botulinum-A toxin effects on rat jaw muscle spindles. Acta Oto-Laryngol 1993;113:400-404.
88. Dressler D, Munchau A, Bhatia KP, et al. Antibody-induced botulinum toxin therapy failure: can it be overcome by increased botulinum toxin doses? Eur Neurol 2002;47:118-121.
89. Comella CL, Jankovic J, Daggett S, et al. Interim results of an observational study of neutralizing antibody formation with the current preparation of botulinum toxin type A treatment for cervical dystonia. Neurology 2004;62(7 Suppl 5):A511.
90. Brans JW, Lindeboom R, Snoek JW, et al. Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial. Neurology 1996;46:1066-1072.
91. Brashear A, Gordon MF, Elovic E, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med 2002;347:395-400.
92. Gelber DA, Good DC, Dromerick A, et al. Open-label dose-titration safety and efficacy study of tizanidine hydrochloride in the treatment of spasticity associated with chronic stroke. Stroke 2001;32:1841-1846.
93. Naumann M, Jankovic J. Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin 2004;20:981-990.